Key Points
- Bioventures 2014 L.P. Mpm sold 26,522 Entrada Therapeutics shares at an average price of $7.54, generating $199,975.88. The sale reduced its position by 0.61%, leaving it with 4.33 million shares valued at approximately $32.67 million.
- Entrada Therapeutics shares were down 8.1%, opening at $7.00, while the company reported a quarterly loss of $1.01 per share and revenue of $0.90 million—both weaker than analyst expectations.
- Despite mixed analyst views, the stock carries a consensus “Moderate Buy” rating with a $17.75 price target; institutional investors own 86.39% of the company’s shares.
Entrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) major shareholder Bioventures 2014 L.P. Mpm sold 14,569 shares of Entrada Therapeutics stock in a transaction that occurred on Wednesday, August 26th. The shares were sold at an average price of $7.06, for a total transaction of $102,857.14. Following the completion of the sale, the insider owned 4,318,348 shares of the company's stock, valued at $30,487,536.88. This trade represents a 0.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Large shareholders that own more than 10% of a company's shares are required to disclose their transactions with the SEC.
Bioventures 2014 L.P. Mpm also recently made the following trade(s):
- On Tuesday, August 25th, Bioventures 2014 L.P. Mpm sold 26,522 shares of Entrada Therapeutics stock. The stock was sold at an average price of $7.54, for a total transaction of $199,975.88.
- On Monday, August 24th, Bioventures 2014 L.P. Mpm sold 21,623 shares of Entrada Therapeutics stock. The stock was sold at an average price of $7.34, for a total transaction of $158,712.82.
Entrada Therapeutics Trading Down 8.1%
Entrada Therapeutics stock opened at $7.00 on Thursday. Entrada Therapeutics, Inc. has a 1 year low of $5.02 and a 1 year high of $16.45. The company has a market cap of $272.58 million, a PE ratio of -1.77 and a beta of -0.26. The company's 50-day moving average is $7.08 and its two-hundred day moving average is $9.36.
Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($1.01) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.97) by ($0.04). Entrada Therapeutics had a negative net margin of 3,537.73% and a negative return on equity of 57.61%. The business had revenue of $0.90 million during the quarter, compared to analyst estimates of $2.32 million. Research analysts forecast that Entrada Therapeutics, Inc. will post -4.03 EPS for the current year.
Institutional Trading of Entrada Therapeutics
Several institutional investors and hedge funds have recently modified their holdings of the business. State of Wyoming purchased a new stake in Entrada Therapeutics in the second quarter valued at approximately $37,000. Russell Investments Group Ltd. lifted its position in Entrada Therapeutics by 72.7% in the 3rd quarter. Russell Investments Group Ltd. now owns 8,808 shares of the company's stock worth $51,000 after buying an additional 3,707 shares during the last quarter. Occudo Quantitative Strategies LP purchased a new stake in Entrada Therapeutics in the second quarter worth approximately $68,000. Jain Global LLC purchased a new stake in shares of Entrada Therapeutics in the 3rd quarter valued at $69,000. Finally, IHT Wealth Management LLC purchased a new stake in Entrada Therapeutics during the second quarter valued at about $72,000. Hedge funds and other institutional investors own 86.39% of the company's stock.
Wall Street Analysts Forecast Growth
Several equities analysts recently commented on the stock. Guggenheim dropped their price objective on shares of Entrada Therapeutics from $20.00 to $17.00 and set a "buy" rating for the company in a research note on Monday, June 8th. Roth Capital reaffirmed a "buy" rating and issued a $11.00 target price on shares of Entrada Therapeutics in a research report on Wednesday, August 12th. Weiss Ratings downgraded Entrada Therapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Thursday, August 13th. Finally, HC Wainwright cut shares of Entrada Therapeutics from a "buy" rating to a "neutral" rating in a research report on Friday, May 8th. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $17.75.
View Our Latest Report on TRDA
Entrada Therapeutics Company Profile
(
Get Free Report)
Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.
The company's pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
